2026-04-13T05:45:56Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1768642025-12-05T13:11:11Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study Echarri, Ana Vera, Isabel Ollero, Virginia Arajol, Claudia Riestra, Sabino Robledo, Pilar Calvo, Marta Gallego, Francisco Ceballos, Daniel Castro Senosiain, Beatriz Aguas, Mariam García López, Santiago Marín Jiménez, Ignacio Chaparro, María Mesonero, Francisco Guerra, Iván Guardiola, Jordi Nos, Pilar Muñiz, Javier MediCrohn study investigators Aplicacions mòbils Telecomunicació en medicina Malaltia de Crohn Mobile apps Telecommunication in medicine Crohn's disease Objectives: Mobile apps are useful tools in e-health and self-management strategies in disease monitoring. We evaluated the Harvey-Bradshaw index (HBI) mobile app self-administered by the patient to see if its results agreed with HBI in-clinic assessed by a physician. Methods: Patients were enrolled in a 4-month prospective study with clinical assessments at months 1 and 4. Patients completed mobile app HBI and within 48 h, HBI was performed by a physician (gold standard). HBI scores characterized Crohn's disease (CD) as remission <5 or active ≥5. We determined agreement per item and total HBI score and intraclass correlation coefficients (ICCs). Bland-Altman plot was performed. HBI changes in disease activity from month 1 to month 4 were determined. Results: A total of 219 patients were enrolled. All scheduled assessments (385 pairs of the HBI questionnaire) showed a high percentage of agreement for remission/activity (92.4%, κ = 0.796), positive predictive value (PPV) for remission of 98.2%, and negative predictive value of 76.7%. High agreement was also found at month 1 (93.15%, κ = 0.82) and month 4 (91.5%, κ = 0.75). Bland-Altman plot was more uniform when the HBI mean values were <5 (remission). ICC values were 0.82, 0.897, and 0.879 in all scheduled assessments, 1 and 4 months, respectively. Conclusions: We found a high percentage of agreement between patients' self-administered mobile app HBI and in-clinic physician assessment to detect CD activity with a remarkably high PPV for remission. The mobile app HBI might allow a strict control of inflammation by remote monitoring and flexible follow-up of CD patients. Reduction of sanitary costs could be possible. 2021-04-28T15:28:23Z 2021-04-28T15:28:23Z 2020-01-26 2021-04-28T15:28:24Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1089/tmj.2018.0264 Telemedicine Journal and e-Health, 2020, vol. 26, num. 1, p. 78-86 https://doi.org/10.1089/tmj.2018.0264 cc by (c) Echarri et al., 2019 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Mary Ann Liebert Articles publicats en revistes (Ciències Clíniques)